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AS ankylosing spondylitis 
ASPE allele-specific primer extension 
DAISY Diabetes Autoimmunity Study in the Young 
DIPP Diabetes Prediction and Prevention 
Eu europium 
IDDM insulin-dependent diabetes mellitus 
HLA human leukocyte antigen 
LNA locked nucleic acid 
MHC major histocompatibility complex 
OLA oligonucleotide ligation assay 
PANDA Prospective Assessment in Newborns for Diabetes  
Autoimmunity 
PCR polymerase chain reaction 
PVR poliovirus receptor 
SBCE single base chain extension 
SNP single nucleotide polymorphism 
SSO sequence-specific oligonucleotide 
SSP sequence-specific priming 
T1D type 1 diabetes 
Tb terbium 
TEDDY The Environmental Determinants of Diabetes in the  
Young 
Tm melting temperature 







The increasing incidence of type 1 diabetes has led researchers on a quest to 
find the reason behind this phenomenon. The rate of increase is too great to be 
caused simply by changes in the genetic component, and many environmental 
factors are under investigation for their possible contribution. These studies 
require, however, the participation of those individuals most likely to develop 
the disease, and the approach chosen by many is to screen vast populations to 
find persons with increased genetic risk factors. The participating individuals 
are then followed for signs of disease development, and their exposure to 
suspected environmental factors is studied. 
 
The main purpose of this study was to find a suitable tool for easy and 
inexpensive screening of certain genetic risk markers for type 1 diabetes. The 
method should be applicable to using whole blood dried on sample collection 
cards as sample material, since the shipping and storage of samples in this 
format is preferred. However, the screening of vast sample libraries of 
extracted genomic DNA should also be possible, if such a need should arise, 
for example, when studying the effect of newly discovered genetic risk 
markers. 
 
The method developed in this study is based on homogeneous assay chemistry 
and an asymmetrical polymerase chain reaction (PCR). The generated single-
stranded PCR product is probed by lanthanide-labelled, LNA (locked nucleic 
acid)-spiked, short oligonucleotides with exact complementary sequences. In 
the case of a perfect match, the probe is hybridised to the product. However, if 
even a single nucleotide difference occurs, the probe is bound instead of the 
PCR product to a complementary quencher-oligonucleotide labelled with a 
dabcyl-moiety, causing the signal of the lanthanide label to be quenched.  
 
The method was applied to the screening of the well-known type 1 diabetes 
risk alleles of the HLA-DQB1 gene. The method was shown to be suitable as 
an initial screening step including thousands of samples in the scheme used in 
the TEDDY (The Environmental Determinants of Diabetes in the Young) study 
to identify those individuals at increased genetic risk. 
 
The method was further developed into dry-reagent form to allow an even 
simpler approach to screening. The reagents needed in the assay were in dry 
format in the reaction vessel, and performing the assay required only the 
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addition of the sample and, if necessary, water to rehydrate the reagents. This 







Type 1 diabetes (T1D) is one example of a multitude of multifactorial diseases 
with a genetic and an environmental component. In T1D, like many other 
autoimmune diseases in this group, genes within the HLA (human leukocyte 
antigen) region are most important in the genetic component. T1D has a special 
position as a childhood disease with a large number of cases in small children 
and a very strong, although complex, HLA association. Approximately fifty 
percent of the genetic component is contributed by the HLA genes on 
chromosome 6, the DR and DQ being the most important factors (Mehers and 
Gillespie 2008; Ounissi-Benkalha and Polychronakos 2008). The genetic 
component alone is not sufficient for the development of the disease, since 
many of those with a strong genetic risk are not affected, but the contribution 
of environmental factors triggering the disease is crucial. The disease itself 
results from the destruction of insulin producing pancreatic beta cells by an 
autoimmune mechanism, and after the loss of insulin production, lifelong 
treatment with insulin is needed. 
 
The incidence of T1D is increasing worldwide, with Finland having the highest 
incidence in the world. In 2005, the incidence rate in Finland was greater than 
60 affected children per 100 000 children per year, and even further increases 
in the incidence rates in the future are predicted (Harjutsalo et al. 2008; Mehers 
and Gillespie 2008). The increasing incidence rate over recent decades remains 
unexplained; the genetic component can not be accountable due to the rapidity 
of the growth of the incidence rates (Mehers and Gillespie 2008; Patterson et 
al. 2009). Therefore, many environmental factors have become the focus of 
interest in studies attempting to find the causes behind the development of the 
disease.  
 
Studies searching for the environmental factors of T1D need tools for finding 
those individuals with an increased genetic risk for disease development. These 
individuals are then included in follow-up programs with the purpose of tracing 
the possible factors triggering the autoimmune process. Since the contribution 
of the HLA genes is well-known and a considerable factor of the genetic 
component, many assays have been developed for deciphering the alleles of the 
genes in the region. An ideal method would be fast and inexpensive, have a 
high-throughput, and produce all the genetic information required to assess the 
genetic risk of an individual according to the knowledge available. With the 
enormity of genetic factors affecting disease susceptibility, many still unknown 
Introduction 
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restrictions to the numbers of analytes used in the risk assessment have usually 
been made for the assays to be conceivable. 
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2 Review of the literature 
 
2.1 Human leukocyte antigen (HLA) 
 
2.1.1 Structure and function 
 
HLA (human leukocyte antigen) is the human version of the major 
histocompatibility complex (MHC) containing many genes related to the 
functions of the immune system. It is located on chromosome 6 and contains 
over 200 genes, and it is known to be the most polymorphic genetic system of 
the human genome. The HLA region is divided into three groups of genes: 
class I, class II and class III, of which the class III genes are structurally and 
functionally different from the two other classes, but are named thus due to 




Figure 1. A simplified diagram of the HLA region in chromosome 6 with a limited number of 
genes shown.  
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Among class I genes there are three classic transplantation genes, HLA-A, -B 
and –C, which encode the α-polypeptide chains of the class I molecules. There 
are also the non-classical HLA–E, -F and -G–genes in addition to some non-
expressed pseudogenes. The β-chain of the class I molecules is coded by the 
beta2-microglobulin gene outside the HLA region in chromosome 15, and this 
chain combines with the α-chain to form the complete molecule (Figure 2). 
(Marsh et al. 2000) 
 
There are five isotypes of class II molecules, HLA-DM, -DO, -DP, -DQ and 
-DR, each consisting of two chains, α and β, encoded by the A and B genes, 
respectively. The α and β chains are roughly similar in size and they form 
heterodimeric (αβ) protein receptors molecules. Both the α and β chains have 
two extracellular domains, a transmembrane region, and a cytoplasmic tail 
(Figure 2). Among the functional class II genes there are also pseudogenes, 
such as DQA2 and DQB2. HLA-DR is rather complex in structure as it 
consists of several functional β-chain genes as well as pseudogenes, the 
number of which can vary. (Marsh et al. 2000) 
 
 
Figure 2. The structure of HLA class I and class II molecules.  
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Class II genes are typically expressed by a subgroup of immune cells, 
including B cells, activated T cells, macrophages and dendritic cells, while 
class I genes are expressed in most somatic cells although at variable levels 
depending on the tissue. Both class I and II molecules function as the 
presenters of short peptides to T cells, class I molecules mostly for endogenous 
and class II for exogenous proteins, although this division is not absolute 
(Klein and Sato 2000a; Turner 2004). 
 
The polymorphisms in class I and II genes are not evenly distributed but are 
concentrated in regions coding for the peptide binding domains of the HLA 
molecule: the α1 and α2 domains of class I molecules, coded by the exons 2 
and 3; and the α1 and β1 domains of class II molecules coded by exon 2 of the 
respective genes. The DR isoform is an exception with a monomorphic α chain 
(Marsh et al. 2000). The amino acid changes in these positions modify the 
peptide-binding specificity by altering the shapes of the antigen-binding 
groove, resulting in a repertoire of molecules with different specificities. The 
number of different alleles discovered for these highly polymorphic HLA loci 
has been increasing steadily. According to the IMGT/HLA database 
(http://www.ebi.ac.uk/imgt/hla/, accessed June 9th 2009) (Robinson et al. 2009) 
the sequence of almost 2500 class I alleles and over 1000 class II alleles has 
been deciphered. 
 
An important aspect of the HLA region is linkage disequilibrium, referring to 
the phenomenon of recombination occurring very rarely between two loci. 
Thus certain alleles of, for example, DQB1- and DQA1-genes are almost 
always inherited together (Bodmer 1987; Tomlinson and Bodmer 1995). This 
phenomenon can be utilised by deducing the allele of a gene from the typing 
information of another gene that is known to be in linkage disequilibrium. For 
example, the HLA-DQB1*0302-allele is found to be in linkage disequilibrium 
with DQA1*03-alleles (Klitz et al. 2003). 
 
 
2.1.2 The nomenclature of HLA alleles 
 
A committee for HLA nomenclature was formed in 1965, and the names were 
originally based on serological results. The current system was introduced in 
1987 with each HLA allele name having a four, six or eight digit number, of 
which all alleles have the four digit number and the longer ones are used if 
necessary. The first two digits specify the group, often corresponding to the 
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serological antigen. For example, DRB1*04 signifies a group of alleles which 
encode the DR4 antigen. The third and fourth digits are used to list the 
subtypes, which are assigned according to the order in which the sequences are 
determined, such as DRB1*0401 and DRB1*0402, which refer to two different 
alleles. The fifth and sixth digits are used to separate non-coding substitutions, 
for example, DRB1*040101 and DRB1*040102. The seventh and eight digits 
separate alleles that differ only in the introns or in the 5' or 3' untranslated 
regions that flank the exons and introns. (Marsh et al. 2004, The HLA 
Informatics Group, Anthony Nolan Research Institute –website: 
http://www.anthonynolan.org.uk/research/hlainformaticsgroup/, accessed May 
26th 2009.) 
 
Alleles that are not expressed due to substitutions introducing premature stop 
codons or insertions or deletions altering the reading frame are called null 
alleles and a suffix ‘N’ is added to the number. Other suffixes are ‘L’ for low 
expression as compared to normal and ‘S’ denoting a secreted molecule not 
present on the cell surface. 
 
 
2.2 HLA and disease 
 
Initial interest in HLA was due to the need for avoiding rejection reactions in 
transplantations, in which the matching of the HLA type of the donor and the 
recipient is of utmost importance (Marsh et al. 2000). Since then the classical 
HLA class I and II genes have been associated with over 100 diseases, 
including most autoimmune diseases, and interest in HLA typing has stretched 
beyond the field of transplantation medicine to diseases such as T1D, 
rheumatoid arthritis, celiac disease, narcolepsy and asthma. For a review see 
Shiina et al. 2004; Gough and Simmonds 2007; Caillat-Zucman 2009. The 
relationship between the HLA and disease is often complicated, and nearly all 
HLA-associated diseases are multifactorial polygenic diseases with other 
genetic as well as environmental factors involved in disease susceptibility 
(Caillat-Zucman 2009). In addition to autoimmune diseases, the HLA region is 
also associated with the course of many infectious diseases, such as human 
immunodeficiency virus infections, malaria and tuberculosis (Klein and Sato 
2000b; Blackwell et al. 2009). 
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2.2.1 Type 1 diabetes 
 
In T1D the insulin production of an individual is compromised due to the 
destruction of the pancreatic β cells by an autoimmune process eventually 
leading to an inability to maintain normal blood glucose levels. Although the 
exact trigger of the onset of the disease is not known, both genetic and 
environmental factors are known to contribute to the process. For a recent 
review see Morran et al. 2008. 
 
Although multiple genes have been suggested to play a role in disease 
susceptibility, the HLA region remains the major genetic risk factor. There is 
also strong evidence for the association of the insulin gene region in 
susceptibility to the disease (Bell et al. 1984; Bennett et al. 1995). Other genes 
involved in disease susceptibility include the CTLA-4- (cytotoxic T-
lymphocyte antigen) (Nistico et al. 1996), PTPN22-(the gene encoding the 
lymphoid protein tyrosine phosphatase) (Bottini et al. 2004) and the IFIH1- 
(interferon induced with helicase C domain 1) (Smyth et al. 2006) genes. (For 
a review see Kelly et al. 2001; Mehers and Gillespie 2008.) Among the 
suspected environmental influences are dietary factors, such as exposure to 
cow’s milk or cereals, and different viral infections (Gillespie 2006; TEDDY 
Study Group 2008). 
 
 
2.2.2 The genetic risk for type 1 diabetes conferred by the 
HLA region 
 
At least three major genes from the HLA region, namely HLA-DRB1, -DQB1 
and -DQA1, contribute to the genetic risk for T1D, but other genes may also be 
involved (Singal and Blajchman 1973; Nerup et al. 1974; Cudworth and 
Woodrow 1975; Platz et al. 1981; Owerbach et al. 1988; Erlich et al. 1990; 
She 1996; Noble et al. 2002; Valdes et al. 2005; Nejentsev et al. 2007). The 
identification of the effects of individual genes is complicated by the strong 
linkage disequilibrium between the HLA genes; recombination events are rare 
and certain alleles of the loci are usually inherited together. The contribution of 
the HLA region to genetic risk is estimated to be approximately 50 percent 
(Risch 1987; Cox et al. 2001; Ounissi-Benkalha and Polychronakos 2008). The 
most important DQB1 alleles influencing disease risk are *02 and *0302, 
which increase disease susceptibility, and *0602 which has a protective effect. 
Table 1 shows examples of a number of haplotypes combined from the DQB1-, 
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DQA1- and DRB1-alleles conferring either disease susceptibility or protection. 
The DQA1- and DRB1-alleles further define the calculated risk. For example, 
in Caucasian populations of the DQB1*0302-DRB1*0401/2/4/5 and the 
DQB1*0302-DRB1*0403 haplotypes the latter is moderately protective, and of 
the DQB1*0302-DRB1*0401 and the DQB1*0302-DRB1*0404 haplotypes 
the latter is only moderately predisposing (Thomson et al. 2007; Erlich et al. 
2008). The disease risk of an individual is estimated from the combination of 
both haplotypes, the DQB1*02-DQA1*05/DQB1*0302-DRB1*0401/2/4/5-
genotype being associated with the most increased risk. (Nejentsev et al. 1999; 
Ilonen et al. 2000; Ilonen et al. 2002) 
 
Table 1. HLA-DR-DQ haplotypes associated with increased or decreased disease risk in 
























2.2.3 Ankylosing spondylitis and HLA-B*27 
 
Ankylosing spondylitis (AS) is a chronic, inflammatory arthritis, causing pain 
in the lower back, and resulting eventually in the fusion of the spine and thus 
causing rigidity of the spine. Disease onset is typically around 20-30 years, and 
males are more often affected than females. For a review see Gladman 1998; 
Kataria and Brent 2004; Reveille 2006. The association of the HLA-B27 
antigen with AS was demonstrated already in 1973 (Brewerton et al. 1973), 
and it has, in addition to narcolepsy and celiac disease, remained among the 
strongest of the variable HLA disease associations reported (Pile 1999; Lin et 
al. 2001; Choo 2007; Caillat-Zucman 2009). The presence of HLA-B*27 is 
almost necessary for disease development with over 90 percent of patients of 
Review of the literature 
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European ancestry being HLA-B*27 positive (Brown et al. 1996; Marsh et al. 
2000; Thorsby and Lie 2005). However, the presence of HLA-B*27 is not 
alone sufficient for disease development. The HLA-B*27 allele is rather 
common in the Caucasian population, 7-14 % of the population being HLA-
B*27 positive, while only 2-5 % actually develop the disease. Consequently, 
the test for the presence of HLA-B*27 can be used as a confirmatory assay if, 
based on other symptoms the patient may have, AS is suspected. (Kataria and 
Brent 2004; Laitinen and Hakala 2005; Caillat-Zucman 2009, dbMHC 
database: www.ncbi.nlm.nih.gov/gv/mhc/, accessed June 9th 2009) 
 
The HLA-B*27 allele is also associated with other diseases, such as reactive 
arthritis and acute anterior uveitis; however, the association is not as strong as 
in the case of AS (Pile 1999; Marsh et al. 2000; Bowness 2002). 
 
 
2.3 Methods used for typing the genetic risk for type 1 
diabetes conferred by the HLA region 
 
Initially, HLA-typing relied on serological methods, but it later became evident 
that these methods were not able to discriminate between all the differences in 
the HLA molecules. When typing down to the nucleotide level became 
possible, the unique complexity of the HLA genes became evident. This typing 
can be low-resolution, which resembles serological typing in the sense that a 
group of alleles, rather than individual alleles, are recognised. With high-
resolution typing, discrimination is down to the individual allele level, and an 
intermediate resolution can be defined as distinguishing some individual alleles 
in addition to groups of alleles. (Marsh et al. 2000) 
 
2.3.1 Studies using HLA screening to identify subjects at risk 
for type 1 diabetes 
 
Several research programs have been screening or are currently screening 
newborns to identify those having an increased genetic risk for type 1 diabetes. 
These high-risk children are then followed with the hope of elucidating the 
factors contributing to disease pathogenesis (Carmichael et al. 2003). Table 2 
lists some of the studies which are using various methods for typing HLA-
based genetic risk, and which are investigating different aspects of T1D 
development, such as environmental and genetic risk factors, and also possible 
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approaches for the prevention of the disease (Rewers et al. 1996; Nejentsev et 
al. 1999; Schenker et al. 1999; Dorman and Bunker 2000; Schatz et al. 2002; 
Hagopian et al. 2006; Hood et al. 2006; TRIGR Study Group 2007). 
 
Table 2. Projects using various methods for the screening of HLA-based genetic risk for T1D.  
The study Typing 
method 




Study in the 
Young 
Dot-blot 
To learn how genes 
and environment 
interact to trigger the 
onset of type 1 
diabetes 
Denver 




To investigate the 
development of 
autoantibodies in 
children of mothers 
or fathers with T1D  
Germany Schenker et al. 1999 



















To understand the 
mechanisms leading 
to the disease and to 
develop a prevention 
therapy 
Florida 




TEDDY – The 
Environmental 
Determinants of 
Diabetes in the 
Young 
DELFIA 
To investigate the 
role of 
environmental 
factors in the 





Hagopian et al. 2006 
http://teddy.epi.usf.edu/ 
TRIGR – Trial 
to Reduce 







To test whether 
hydrolysed infant 
formula compared to 
cow's milk-based 
formula decreases 











One option for the screening of genetic risk is a step-wise approach. Different 
factors influencing risk are analysed with several consecutive assays, and the 
screened population is thus narrowed down to those eligible for the study. The 
number of screened individuals is diminished after each step and the order of 
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the analytes needs to be carefully selected to provide the most economical 
screening program.  
 
A second option for screening is to include all the genetic risk factors in one 
step, requiring a multiplex assay capable of typing all the loci in a single assay. 
The latter approach is usually technically more complex than step-wise typing, 
and is better suited for studies where it is essential to have the full information 
of the genetic risk factors of all the screened individuals. Even with the 
intention of selecting only a small percentage of the population, including those 
with the highest genetic risk, the number of screened samples easily expands to 
several thousand and the selected screening method becomes a critical aspect 
in the study budget. However, once the progress of the disease can be 
prevented or the disease cured the full genetic risk panel of those individuals 
receiving treatment might have a major effect on the chosen therapy, and the 
all-at-once approach of screening would thus be the most advantageous. 
 
 
2.3.2 Dot-blot and reverse dot-blot 
 
The first assay using the basic principle of a dot-blot assay with labelled, 
sequence-specific oligonucleotides (SSO) to detect PCR product immobilised 
onto a membrane (Figure 3) was published in the 1980s (Saiki et al. 1986) and 
has been a popular method ever since. The method was also quickly applied to 
the typing of HLA polymorphisms, such as DQA1- and DQB1 alleles (Morel 
et al. 1988; Dorman et al. 1990; Bugawan and Erlich 1991; Heimberg et al. 
1992). The primers used were designed to include all the polymorphisms of 
interest within the amplicon, and the resulting PCR product was usually 
immobilised onto a membrane by baking or UV cross-linking. Sequence 
specific oligonucleotides with radioactive labels (Dorman et al. 1990; Khalil et 
al. 1990; Heimberg et al. 1992; Berzina et al. 2002) or nonradioactive labels 
with chromogenic dyes or chemiluminescent substrates for detection (Bugawan 
and Erlich 1991; van der Auwera et al. 1995; Rewers et al. 1996) were then 
used to identify the alleles of the immobilised PCR products under 
investigation. 
 
In the reverse dot-blot method (Figure 3) the positions of the PCR product and 
the probes are reversed with the probes being those immobilised onto a solid 
surface and the PCR product labelled for detection and hybridised to the 
probes. With this reversed dot-blot method microtiter plates have been used, 
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instead of membranes, as the solid phase for immobilizing the probes thus 
enabling automation and high-throughput screening of HLA genes (Giorda et 





Figure 3. The principle of dot-blot and reverse dot-blot assays. In dot-blot assays PCR 
products are immobilised onto the solid phase and labelled oligonucleotide probes are 
hybridised to the PCR product, whereas in reverse dot-blot assays the positions of the PCR 
products and probes are reversed. 
 
Studies that have used dot-blot for typing the HLA-DQB1 alleles include the 
NOBADIA (Norwegian Babies against Diabetes) study (Ronningen 1997), the 
German BABYDIAB study (Schenker et al. 1999) and the ABIS (All Babies in 
Southeast Sweden) study (Berzina et al. 2002). In the DEW-IT (Diabetes 
Evaluation in Washington) study glass slides were used instead of nylon 
membranes for immobilizing the PCR products (Wion et al. 2003). The 
DAISY (Diabetes Autoimmunity Study in the Young) study, conducted in 
Denver, Colorado, and initiated in 1994 (Rewers et al. 1996), initially also used 
the dot-blot method for their screening. In addition to these screening programs 
to find individuals with an increased genetic risk for T1D, the dot-blot method 
has also been used in research to further elucidate the genetic risk behind T1D 
(van der Auwera et al. 1995; Erlich et al. 2008) or to evaluate the best possible 
inclusion criteria for follow-up studies (Lampasona et al. 1995). 
Review of the literature 
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A commercial kit for typing HLA-DQB1 alleles called RELI™ SSO with a 
reverse dot-blot principle is available from Invitrogen (Carlsbad, CA, USA). 
Kits for other HLA genes, such as DRB1, are also available in the same 
product line. The RELI™ SSO method, to evaluate the HLA-based genetic risk 
for T1D, has been used in the DIABFIN (Diabetes Finalized Italian Network) 
(Buzzetti et al. 2004) and Prefin Italy (Lorini et al. 2005) studies as well as by 
the JDRF (The Juvenile Diabetes Research Foundation) / Wellcome Trust 
Diabetes and Inflammation Laboratory (DIL) (https://www-
gene.cimr.cam.ac.uk/todd/public_data/HLA/HLA.shtml, accessed 4th March, 
2009). The DAISY study has also proceeded in 2002 to type the samples with a 
reverse line-blot method using strips, performed in the HLA typing laboratory 
at Roche Molecular Systems Inc. (Alameda, CA, USA) (Blair et al. 2002; 
Emery et al. 2005). In this method biotinylated, amplified DNA is hybridised 
to nylon membrane strips containing immobilised probes in linear arrays, and 





The DELFIA® method, using sequence-specific oligonucleotides with 
lanthanide labels closely resembling the dot-blot method performed on a 
microtiter plate, is commercially available from PerkinElmer, Wallac. 
DELFIA® assays are available for screening certain alleles of the HLA-DQB1, 
-DQA1 and DRB1 genes that provide valuable information when evaluating 
the genetic risk for developing type 1 diabetes. This method has been used for 
screening for eligible participants in the DIPP (The Diabetes Prediction and 
Prevention) study in Finland (Nejentsev et al. 1999; Kukko et al. 2004) as well 
as in the TEDDY (The Environmental Determinants of Diabetes in the Young) 
study (The TEDDY Study Group 2007), and also in a Danish study with the 
objective of improving the tools used for predicting of T1D at birth (Eising et 
al. 2007). 
 
In the DELFIA® method the region of interest of the gene under investigation 
is amplified by PCR using a primer pair with one of the primers labelled with 
biotin. As shown in Figure 4, the biotin moiety is then used to attach the PCR 
product onto a microtiter plate well coated with streptavidin which allows the 
removal of all the other components of the PCR by washes. The PCR product 
is then denatured using sodium hydroxide and the non-biotinylated 
complementary strand is removed by washes leaving a single-stranded PCR 
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product in the microtiter well. Lanthanide-labelled probes are added and are 
allowed to hybridise to their complementary sequences in the PCR products. 
The microtiter wells are washed once more, to remove the excess probes, and a 
development solution is added, after which the signals can be measured and the 
results interpreted. (Sjöroos et al. 1995; Ilonen et al. 1996; Sjöroos et al. 1998; 




Figure 4. DELFIA hybridisation. The biotinylated PCR product is attached to the well of a 
streptavidin coated microtiter plate and stripped of the complementary strand. The lanthanide-
labelled probes hybridise to the single-stranded PCR products, and after removal of unbound 
probes by washes, the signals produced by the labels are measured from the wells.  
 
The utilisation of lanthanide labels provides an advantage. Due to their unique 
nature, the biological background of sample material does not interfere with the 
measurement allowing the use of less pure DNA material in the assays. Since 
the sample material need not be pre-treated excessively, valuable time and 
materials are saved.  
 
 
2.3.4 Luminex xMAP –technology 
 
The PANDA (Prospective Assessment in Newborns for Diabetes 
Autoimmunity) study is relying on the Luminex platform for typing the HLA-
DQB1 and –DRB1 –alleles (Hood et al. 2006). Luminex xMap® technology 
(Figure 5) is based on microspheres that are internally labelled with two 
spectrally distinct fluorochromes. The ratio of the fluorochromes is specific for 
each type of microbead, and forms the basis of recognition of different beads. 
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Figure 5. The Luminex assay. The labelled beads have different oligonucleotide probes 
attached onto their surfaces. The beads, and the particular probes attached to them, can be 
recognised through the varying dye ratios of the beads. The amplified and biotinylated PCR 
products are hybridised to the bead sequences, and the biotin is used to label the attached PCR 
products on the beads. The signals are then measured both from the beads, to recognise the 
probe sequence, and the biotin attached label, to identify if a PCR product is hybridised to the 
probe or not. 
 
The beads are coated with capture probes, usually approximately 20 base pairs 
in length, containing a sequence complementary to a sequence in the 
appropriate amplified PCR product (Fulton et al. 1997; Dunbar 2006). The 
sequence of the capture probe is consequently linked to the ratio of the dyes in 
Review of the literature 
25 
the bead enabling the identification of the probe sequence through the bead. 
Primers are designed to amplify a region from 100 to 300 base pairs. As one of 
the primers is biotinylated, biotin is thus incorporated into the PCR product 
during amplification. This biotin is then used for labelling the PCR product 
hybridised to the microsphere with a streptavidin coupled label moiety. Once 
the PCR products are hybridised to the capture probes on the beads, the beads 
are analysed with a flow cytometer capable of measuring the bead 
fluorescence, as well as the signal from the labelled PCR product possibly 
hybridised to the capture sequence of the bead. (Fulton et al. 1997; Itoh et al. 
2005; Dunbar 2006)  
 
A few possible assay formats for analyzing nucleic acids with the Luminex 
principle have been described. In the direct hybridisation format the single-
stranded PCR products, rendered such by denaturing or by asymmetric 
amplification, are hybridised to the capture probes. If the labelling of the target 
DNA is undesirable or not possible, a competitive format can be used, where 
biotinylated single-stranded oligonucleotide targets compete with the double-
stranded PCR products for hybridisation to the capture probes. (Dunbar 2006) 
 
The beads can also be used for analyzing the results of solution-based 
sequence-specific enzymatic reactions used for typing the target sequence. 
These reactions include the allele-specific primer extension (ASPE), the 
oligonucleotide ligation assay (OLA), and the single base chain extension 
(SBCE). In all of these approaches, a capture sequence is included in one of the 
oligonucleotides used in the assays to attach the product to a recognisable bead 
via a complementary sequence on a bead. In ASPE (Figure 6) a primer with a 
capture sequence is extended by the incorporation of dNTPs, one of which is 
biotinylated. The extension can only occur if the 3’-end of the primer, located 
at the site of the polymorphism, is complementary to the target. In OLA 
(Figure 7) a capture probe with the 3’end of the probe positioned at the site of 
the polymorphism and a biotinylated reporter probe are ligated by a 
thermostable ligase provided the probes and target are perfectly matched. 
Unlike in ASPE and OLA, in the SBCE method (Figure 8) the 3’-end of a 
primer containing a capture sequence is located one base upstream of the 
polymorphism. Separate reactions are required for all possible single base 
extensions using biotinylated nucleotides. However, after the extension step the 
detection can be multiplexed into a single reaction. (Dunbar 2006) 
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Figure 6. Allele-specific primer extension (ASPE). A capture sequence is included in the 
primer used for amplification of the target. The 3’-end of the primer is located at the site of the 
polymorphism, and amplification can occur only in the case of a perfect match of the 3’-end. 
One of the dNTPs is biotinylated and this biotin is incorporated into the amplification product. 
The capture sequence is used to attach the biotinylated PCR product to the correct bead, while 
the biotin moieties are used for labelling the product 
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Figure 7. The oligonucleotide ligation assay (OLA). A probe with a capture sequence 
complementary to a sequence on a specified bead and a biotinylated reporter probe are both 
hybridised to the target sequence. A ligation reaction will occur only in the case of a perfect 
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Figure 8. Single base chain extension (SBCE). A primer with a capture sequence hybridises to 
the target with the 3’-end next to the polymorphic site. A biotinylated ddNTP is used to extend 
the primer by a single base. The different ddNTPs, used for typing the different alleles, all 
require separate reactions, and in each reaction a different capture probe is used linking the 
added ddNTP to a specific sequence. The single base extension products from all reactions are 
then mixed with the beads. Through the capture sequence the added ddNTP can be linked to a 
specific bead, and the base added to the site of the polymorphism can thus be identified. 
 
Multiple analytes are easily detected from a single reaction based on the 
identification of the beads and, consequently, the capture probes. The Luminex 
system is reported to be able to analyze up to 100 different analytes in a single 
reaction, thus enabling, if necessary, the typing of several HLA genes in a 
single run (Fulton et al. 1997; Dunbar 2006; Dalva and Beksac 2007). 
Recently, a version of the Luminex system capable of analysing up to 500 
analytes in a single reaction has been released (Luminex-website 
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http://www.luminexcorp.com/flexmap3d/index.html, accessed 14th October 
2009). In this version, three different dyes are used in the beads, instead of two, 
for identification purposes, and thus the number of beads can be increased. The 
Luminex assay principle can also be applied to other analytes beyond nucleic 
acid analysis, such as antigens, antibodies, and enzyme substrates (Fulton et al. 
1997). 
 
Kits for typing HLA alleles, including the DQB1-gene polymorphisms, are 
available from One Lambda Inc. (Canoga Park, CA, USA) and Tepnel 
Lifecodes (Stamford, CT, USA) (Dunbar 2006; Dalva and Beksac 2007). Both 
kits use the direct hybridisation approach, but there are slight differences 
between the kits, for example in the assay protocol. Tepnel Lifecodes relies on 
asymmetric PCR, whereas the One Lambda –kit uses regular PCR. There are 
also differences in the number of probes used for typing of the alleles. (Dunbar 
2006; Dalva and Beksac 2007) Products for typing polymorphisms in other 





A sequence-based typing method called pyrosequencing, originally designed 
for sequencing short stretches of approximately 10 bases of DNA, has also 
been adapted for typing the HLA genes DQB1 and DRB1 (Ringquist et al. 
2002a; Ringquist et al. 2002b; Ringquist et al. 2004; Entz et al. 2005). It has 
been used in the TRIGR (Trial to Reduce IDDM in the Genetically at Risk)  
–project to type samples from the USA and Canada (TRIGR Study Group 
2007). The pyrosequencing method requires a single-stranded DNA-template, 
purified of any residual PCR components, either by solid phase capture of the 
PCR product or by enzymatic removal of any remaining primers and 
nucleotides (Ronaghi 2001). The actual sequencing reaction (Figure 9) consists 
of four steps: (1) A sequencing primer is hybridised to the single-stranded PCR 
product. (2) The sequencing is performed by adding each dNTP one-by-one 
into the reaction, and when the correct dNTP is added to the reaction, it 
becomes incorporated and pyrophosphate is released. (3) The pyrophosphate is 
then converted by ATP sulfurylase, with exogenous adenosine 5’ 
phosphosulfate, into ATP, followed by the production of light with the use of 
luciferase. In the nucleotide additions dATPαS is used instead of dATP since it 
is incorporated efficiently by DNA polymerases, but it is not a substrate for 
luciferase. (4) Unincorporated dNTPs are degraded by apyrase before the 
Review of the literature 
30 
addition of the next dNTP. The production of light is used to determine which 
dNTP was successfully added and thus is the correct base in the studied 
sequence. Steps 2 to 4 are then repeated to further decode the target sequence. 
(Ronaghi et al. 1996; Ronaghi 2001; Fakhrai-Rad et al. 2002; Ringquist et al. 
2002b; Ringquist et al. 2004)  
 
 
Figure 9. Pyrosequencing. I: When a correct dNTP is added, the polymerase incorporates it 
and a pyrophosphate is released. ATP-sulfurylase converts this pyrophosphate into ATP, which 
is then used by luciferase to produce light which is measured to identify a successful 
incorporation. II: If a wrong dNTP is added, incorporation does not occur and the added dNTP 
is removed from the reaction by apyrase. 
 
Based on previous knowledge of the sequences of the region being assayed, the 
dispensation order of the dNTPs can be adjusted, instead of the four different 
dNTPs rigidly following one after another always in the same order (Ramon et 
al. 2003). This adjusted order of dNTP dispensation has also been exploited in 
the typing of HLA-DRB1 alleles in heterozygous DNA samples by using out-
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of-phase dispensation. The order of nucleotides added is selected to cause 
incorporation in only one of the alleles, resulting in the sequencing of this 
allele to be ahead of the other. DRB1-alleles otherwise indistinguishable have 
been successfully typed by this method. (Ramon et al. 2003)  
 
The read lengths obtained when typing the genes of the HLA region have been 
from 30 to 70 nucleotides (Ringquist et al. 2002b; Ringquist et al. 2004; Entz 
et al. 2005), although some methods have been reported that enable the reading 
of sequences up to 150 residues in length (Gharizadeh et al. 2002). The DQB1 
and DRB1 alleles have been completely resolved by using a combination of a 
number of sequencing primers. The primers hybridise to different locations on 
the PCR product, usually in the most polymorphic exon 2 of these genes. 
Consequently, a more complete view of the sequence and the alleles in 
question can be achieved than by using the information gained from a single 
sequence (Ringquist et al. 2002b; Ringquist et al. 2004; Entz et al. 2005; Lu et 
al. 2009). To decipher the DRB1 alleles of a sample, a task complicated by the 
sheer number of different DRB1 alleles, a group-specific amplification as a 
pre-selection step combined with pyrosequencing of the identified sub-groups 
has also been used (Entz et al. 2005). 
 
The unique, highly polymorphic nature of the genes in the HLA region requires 
appropriate software to resolve the alleles in question. However, 
pyrosequencing is a convenient method for the analysis of HLA alleles, and 
provides increased resolution of the region sequenced not obtainable by other 
methods relying on oligonucleotide probes, which dictate in advance the 
sequence information that can be acquired by the method in question. Thus 
previously unpublished polymorphisms can also be discovered by the 
pyrosequencing method. An added benefit of the method is the possibility to 
resolve some allelic combinations by out-of-phase sequencing (Ramon et al. 




2.3.6 Other methods for typing HLA genes 
 
In the well-established TaqMan method (Holland et al. 1991), a DNA-
polymerase with a 5’-nuclease activity is used in PCR to cleave a double-
labelled probe hybridised to the template being amplified by the polymerase. 
When the probe, containing a reporter fluorophore on one end and a quencher 
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label on the other, is cleaved, the reporter label is released and the resulting 
increase in its fluorescence signal can be measured. This principle of detecting 
the amplified PCR product has also been applied to the testing of HLA alleles. 
Faas and colleagues have developed a system based on TaqMan probes to 
analyse HLA-DQB1 alleles where the specificity of the assay relies mostly on 
sequence specific primers (Faas et al. 1996). They noted that the TaqMan 
probes hybridised under PCR conditions to templates containing up to two 
mismatches, and thus were not able to provide the specificity required to 
distinguish the alleles. However, if such a method, based on a repertoire of 
sequence specific primers to identify the alleles, were used, fewer labelled 
probes would be required, since a separate probe would not be needed to detect 
each allele; whereas in a method where generic primers are employed, a larger 
panel of more specific probes would be needed to identify all required alleles. 
This combination of sequence-specific priming (SSP) with TaqMan detection 
has later also been applied to other HLA genes (Luedeck and Blasczyk 1997; 
Menon et al. 1997; Slateva et al. 1998; Albis-Camps and Blasczyk 1999; 
Gelsthorpe et al. 1999; Tremmel et al. 1999; Slateva et al. 2001; Reinton et al. 
2006; Danzer et al. 2007), but despite these developments the utilisation of this 
approach in large-scale screening for the risk alleles for T1D has not been 
reported.  
 
Due to the complex nature of the HLA region, an alternative approach to 
typing the HLA alleles, with the help of single nucleotide polymorphisms 
(SNP), called HLA tagging has been proposed (de Bakker et al. 2006; Goris et 
al. 2008; Leslie et al. 2008). In this method, the HLA alleles are deciphered by 
analysing SNPs that are located outside the HLA genes, but are strongly 
associated with certain HLA alleles. The use of a TaqMan-assay to screen for 
two SNPs identifying DR3/4-DQ8 subjects has been suggested as a primary 
step by Barker and colleagues, since this would identify those individuals 
considered at the highest risk for developing T1D (Barker et al. 2008). One 
SNP was successfully typed by the TaqMan method, but the second SNP was 
assayed using a restriction enzyme digestion, since nearby polymorphisms 
prevented the utilisation of a TaqMan assay with this SNP. Additionally, since 
the association of the SNP to the targeted genotype was not 100 % when 
compared to results obtained by a reverse dot-blot method, the HLA genotype 
of the individuals suspected of a high risk had to be confirmed by other 
methods. This SNP tagging using the TaqMan-method has also been shown to 
be applicable to the detection of HLA risk alleles for celiac disease (Monsuur 
et al. 2008; Koskinen et al. 2009). 
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Commercial kits based on sequence-specific primers are also available for 
typing the HLA genes. These methods were published already in the 1990s, 
and have been widely used (Olerup and Zetterquist 1992; Bunce et al. 1995; 
Welsh and Bunce 1999; Gerlach 2002). The identification of the alleles is 
based on the pattern of PCR products produced by an array of allele-specific 
primer sets, usually visualised by gel-electrophoresis. Qiagen provides Olerup 
SSP –kits for both low and high resolution typing of class I and class II genes 
(Qiagen website: http://www1.qiagen.com/Products/Assays/HLA/, accessed 
April 11th 2009). Invitrogen manufactures two kits relying on the same 
principle of sequence-specific priming: SSP UniTray® and AllSet+™Gold 
SSP (Invitrogen website: http://www.invitrogen.com, accessed April 11th 
2009). 
 
HLA typing can also be done by sequencing. For example, Qiagen offers the 
SBTexcellerator HLA kit, Invitrogen manufactures the SeCore™ kit, and 
Abbott Laboratories the AlleleSEQR kit (Abbot Molecular website: 
http://international.abbottmolecular.com/HLA_1246.aspx, accessed October 
24th 2009). These methods are usually quite labour-intensive and consequently 
not suitable for the primary screening of large sample collections. 
 
The different methods used in the screening for the HLA risk alleles for T1D 
all have their advantages as well as some disadvantages (Table 3). Some of the 
methods, namely the pyrosequencing and the Luminex assay, require a multi-
step sample pre-treatment, while some methods allow the use of quite crude 
sample material, such as whole blood dried on a sample collection paper used 
in the DELFIA system. However, the labour required by some of the methods 
is compensated, for example in the Luminex assay, by the number of alleles or 
analytes than can be analysed simultaneously. The intended use dictates to a 
great extent which of the assays is the most suitable for the purpose. 
Considering a study aimed at the screening of thousands of samples, such as 
the TEDDY study, a method with minimal costs combined with fast production 
of results would be ideal. The costs of an assay usually mainly consist of 
labour and reagents. Thus an economical method would require minimal 
hands-on time and inexpensive reagents as well as minimal sample pre-
treatment, and would not require the use of specialised equipment.  
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Table 3. Characteristics influencing the method of choice for screening the HLA risk alleles. 
Method Advantages Drawbacks 
dot-blot -no complicated sample pre-
treatment 
-simple method principle – 
easily applied to new analytes 
-limited number of alleles 
detected simultaneously 
Luminex -number of alleles detected 
simultaneously can vary from 








DELFIA -no complicated sample pre-
treatment 
-limited number of alleles 
detected simultaneously 
TaqMan -uncomplicated assay 
principle requiring only up to 
2 steps 
-limited number of alleles 
detected simultaneously 




At present there is no cure or method of prevention for type 1 diabetes. 
Screening for the genetic risk for T1D is currently used to identify those 
individuals eligible for prevention trials (Dantonio et al. 2006). It has also been 
stated that until an effective intervention is available, this should be the only 
purpose of the genetic screening of the general public (Schatz et al. 2002). 
Several studies have focused on identifying environmental factors that are 
thought to contribute to the disease susceptibility. Possible ways of preventing 
the disease or delaying the disease progress can be investigated, and also 
deeper knowledge of the molecular mechanisms behind the disease can be 
gained by studying individuals with increased genetic risk (Schatz et al. 2002; 
Gillespie 2006; Mehers and Gillespie 2008). Hopefully in the future T1D can 
be prevented and the methods developed for screening genetic risk factors can 
be applied to population screening programs, and possibly even identify those 
preventive measures most suited for the individual with a certain genetic risk 
for T1D. (Knip 1998; Schatz et al. 2002; Kim and Polychronakos 2005) 
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3 Aims of the study 
 
The aim of the present study was to improve the current methods used in the 
screening for the genetic risk for type 1 diabetes in order to reduce the costs 
and time spent in analyzing the samples. More specifically, the aim was to 
develop a method generally suitable for the screening of blood samples dried 
on sample collection paper for different polymorphisms. 
 
The aims of the original publications were as follows: 
  
1. To provide proof-of-principle for a method based on asymmetric 




2. To develop the method created further to suit a more complex assay 
for HLA-DQB1 screening and to develop a method allowing the use 
of whole blood dried on sample collection paper as sample material. 
 
 
3. To show the functionality of the method developed in a large-scale 
screening program involving the typing of thousands of samples. 
 
 
4. To provide a possible dry reagent approach to further simplify the 
method developed and to compare the method developed to an 
existing method used in a routine screening program. 
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4 Summary of materials and methods 
 
A summary of the materials and methods used and some unpublished 
information is presented in this chapter. A more detailed description of the 





The detailed sequences and labels of the oligonucleotide primers and probes 
are described in the original publications (I-IV) and in Table 4. The primers 
and probes for study I were purchased from MWG Biotech AG (Ebersberg, 
Germany) and for studies II-IV from ThermoElectron GmbH (Ulm, Germany). 
The lanthanide probes were labelled at the Department of Biotechnology at the 
University of Turku (I and II) or at Abacus Diagnostica (Turku, Finland) (III 
and IV). 
 
The LNA (locked nucleic acid)-spiked probes were designed according to 
published guidelines (Orum et al. 1999; Braasch and Corey 2001; Simeonov 
and Nikiforov 2002; Costa et al. 2004; Ugozzoli et al. 2004; You et al. 2006) 
and with the aid of web-based calculation programs (http://lnatools.com) suited 
for the design of LNA-spiked probes.  
 
 
4.2 DNA samples and sample pre-treatment 
 
The whole blood samples used in the studies were collected for genetic studies 
from Finnish type 1 diabetic families (I, II), and from population-based birth 
cohorts in Germany and from the three cities in Finland, Turku, Oulu and 
Tampere, participating in the TEDDY and DIPP studies (III). Samples 
originally drawn for diagnostic purposes were also used as reference material 
in IV for the development of a new method.  
 
DNA was extracted from EDTA (ethylenediaminetetraacetic acid) -treated 
blood with a salting-out method (Olerup and Zetterquist 1992). The HLA-
DQB1 genotypes of the samples were determined using a time-resolved 
fluorometry-based DELFIA® plate hybridisation assay (Perkin Elmer Life and 
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Analytical Sciences Wallac, Turku, Finland) (Sjöroos et al. 1995; Nejentsev et 
al. 1999). The insulin gene -2221 C/T–polymorphism (Laine et al. 2004; Laine 
et al. 2007) and the presence of HLA-B*27 (Välimaa et al. 1998) were also 
typed using DELFIA®-based plate hybridisation methods. For the poliovirus 
receptor (PVR)-A/G-SNP and the CD86-gene exon 2 A/G-SNP sequencing 
was used as a reference method. 
 
EDTA-treated blood was also used in testing the possibility of using FTA® 
Classic Card (Whatman International Ltd., Maidstone, UK) sample collection 
cards as sample material. In order to use dried blood spots in the homogeneous 
assay format, a pre-treatment strategy to liberate the DNA from the blood spots 
into solution was needed. An approach where circles 3 mm in diameter were 
cut from the FTA cards into the wells of a PCR plate, incubated in water for 
ten minutes at 100 °C, and cooled to 10 °C and briefly centrifuged was found 
successful. 1 µl volumes of this solution per reaction were then used as the 
source of sample DNA. A slightly modified approach, including a washing step 
with 50 mM sodium hydroxide before the addition of water, was needed when 
the blood was spotted onto 903 ProteinSaver™ cards (Whatman International 
Ltd). (II, III) 
 
 
4.3 The assay principle 
 
The basic principle behind all assays developed is the same, relying on 
asymmetric PCR and post-PCR hybridisation of lanthanide-labelled probes 
with either single-stranded PCR product or complementary quencher 
oligonucleotides. In homogeneous assays, also known as closed tube assays, no 
separation steps are required: the unreacted label is not removed from the 
reaction; instead the PCR products can be detected without opening the 
reaction vessel (Higuchi et al. 1992). The benefits of homogeneous assays have 
long been accepted, compared to assays requiring separate post-PCR analysis 
steps (Foy and Parkes 2001). The assays developed are all homogeneous with 
all reagents needed to complete the analysis included in the PCR mix. After 
preparing the reactions and adding the samples, only thermal cycling and signal 
measurement are required.  
 
The method developed requires the amplification of the PCR to be asymmetric, 
using an excess of one primer, in order to create single-stranded PCR product 
during thermal cycling (Gyllensten and Erlich 1988). This single-stranded PCR 
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product is then available for the probes to hybridise to after the thermal cycling 
is completed. 
 
The probes used in these assays are short, and do not hybridise in the high 
temperature used during PCR amplification. Instead, once the amplification is 
finished and the temperature of the reactions is slowly lowered to room 
temperature, the probes hybridise to their complementary sequences. The 
principle behind the competitive hybridisation (Morrison et al. 1989; Li et al. 
2002; Shengqi et al. 2002) of the probes and PCR products is described in 
Figure 10. Should the single-stranded PCR product contain a complementary 
sequence to the lanthanide-labelled probe, the probe can hybridise to this 
product instead of its complementary quencher oligonucleotide, and the 
fluorescence of the probe is not quenched. However, if the PCR product does 
not contain a complementary sequence, with as little as a single base difference 
in sequence, or if there is no PCR product due to failed amplification, the 
lanthanide probe binds to the complementary quencher and the fluorescence of 
the probe is quenched. 
 
 
Figure 10. The possible hybridisations of the probes and quenchers. If the PCR product 
contains a complementary sequence the probe hybridises to it resulting in a high fluorescence 
signal. If the PCR product contains even a single nucleotide mismatch or there is no PCR 
product present due to failed amplification, the probe binds to its complementary quencher 
oligonucleotide and the signal from the probe is quenched. 
 
 
A Victor 1420 Multilabel Counter (PerkinElmer, Wallac, Turku, Finland), with 
the default parameters of the instrument, was used for the measurement of 




single-stranded PCR product 
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signals in all the assays developed. The signal-to-background ratios were 
calculated for each of the probes by dividing the mean of the measured signal 
from the sample by the mean of the appropriate background, this being either a 




4.4 The SNP assays 
 
The details of the reaction conditions of the SNP assays for the insulin gene 
-2221 C/T, the PVR-A/G and the CD86 gene exon 2 A/G polymorphisms are 
given in publication I. In all three assays one primer pair and two pairs of 
probes were used to detect the two possible alleles of each SNP according to 
the principle outlined above. The samples were divided into three genotype 
groups according to the signal-to-background ratios of both probes, since for 
each SNP only three genotypes were possible.  
 
 
4.5 HLA-DQB1 screening 
 
The HLA-DQB1-screening assay differed from the SNP assay in that 
genotyping single SNPs was not possible due to the complex nature of the 
typed HLA-DQB1 gene. Instead, probes that recognise short stretches of 
sequence, appearing in only one or a few alleles, were used. The genotypes of 
the samples were then deduced from the patterns produced by positive signals. 
 
The typing scheme for the HLA-DQB1 gene was based on a heterogeneous 
DELFIA® assay previously developed in our laboratory (Sjöroos et al. 1995) 
and the details of the assay are described in publication II. Five probe-quencher 
pairs were used to recognise the DQB1 alleles *02, *0301, *0302, *0602/3 (II) 
and *0603/4 (unpublished). A probe hybridising to a consensus sequence found 
in all DQB1 alleles was also included in the assay, so that the possible failures 
in the amplification could be detected.  
 
Due to the specific requirements imposed by the TEDDY study to the 
screening of the HLA-DQB1 conferred genetic risk, the probes used in the 
homogenous assay were further adjusted in publication III. The changes were 
made to provide a simple and fast primary screening step to be used for the 
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typing of thousands of samples and also, with the eligibility criteria in mind, to 
minimise the number of samples requiring more detailed genotyping.  
 
The repertoire of probes currently available for typing the HLA-DQB1 alleles 
with the homogeneous assay developed has expanded since, and is shown in 
Table 4. (II, III, unpublished) 
 
Table 4. Probes available for typing the HLA-DQB1 alleles in the homogeneous assay format. 
The LNA-bases are marked with underlined, bold letters. The lanthanide label, europium (Eu) 
or terbium (Tb) is always placed in the 5’-end of the probe and the dabcyl moiety in the 3’-end 
of the quencher oligonucleotide. The concentrations of the probe and the complementary 
quenchers in the reactions are shown. (II, III, unpublished) 
target 









*02 AAG AGA TCG TG Tb 0,33 CGC ACG ATC TCT 2,66
*0302 GCC GCC TGC CG Eu 6,6 GGC AGG CGG 33,2
*0301 TGG AGG TGT AC Eu 6,6 CGG TAC ACC TCC 33,2
*0301/3 GCC GCC TGA CG Tb 3,3 CGT CAG GCG G 16,6
*04 AAC GGG ACC GAG C Eu 5,0 GCT CGG TCC CGT T 39,9
*04/5 TGC GGG GTG TGA C Tb 1,66 GTC ACA CCC CGC A 5,0
*05/6 GGG CGG CCT Tb 3,3 AGG CCG CCC 6,6
*0501 ACCGGGCAGTGA Eu 13,8 TCACTGCCCGGT 13,8
*0602/3 TAC CGC GCG Tb 3,3 CGC GCG GTA 6,6
*0603/4 TTG TAA CCA GAC AC Eu 16,6 GTG TCT GGT TAC A 33,2
all (control) CGC TTC GAC AG Eu 6,6 CTG TCG AAG CG 66,4  
 
 
4.6 HLA-B*27 screening with the dry reagent approach 
 
In HLA-B*27 screening the specificity of the assay relies on both allele-
specific primers and an allele-specific probe. The details of the assay are 
described in publication IV. In short, the B*27-specific primers are used to 
amplify only the B*27 alleles, if the specific alleles are present in the sample, 
and the terbium-labelled probe is used to recognise the PCR product. Since 
only the B*27 alleles are amplified with these primers, a second pair of primers 
amplifying a section of the β-actin gene is used to control the success of the 
amplification, and this PCR product is detected by a europium-labelled probe. 
 
The feasibility of a dry reagent approach was studied by drying all the reagents 
needed in the PCR to a well on a PCR plate. The drying of the enzyme was 
tested together with the other reagents in addition to drying it separately from 
other reagents. The stability of the reagents at room temperature sealed into 
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storage packages, and protected from light was monitored over the period of 
eighteen weeks. 
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5 Summary of results and discussion 
 
5.1 The SNP assays 
 
The functionality of the approach developed was first demonstrated in three 
basic SNP assays (I). The hybridisation patterns of the europium- and terbium-
labelled probes are described in the upper part of Figure 11 with respect to the 
results of the SNP assays, and the lower part of Figure 11 shows genotyping 
results produced by the insulin gene -2221 C/T and the PVR-A/G assays. The 
three differing genotypes of all three SNP assays, the insulin gene -2221 C/T 
polymorphism, the PVR-A/G-polymorphism and the CD86 gene exon 2 A/G-
polymorphism, were clearly distinguishable, providing support for the 
functionality of the chosen approach. Moreover, of the hundreds of samples 
typed, only a very small number required reanalysis, varying from 0.3 to 5 
percent of samples. 
 
The chosen probe format of two complementary oligonucleotides both with a 
single label moiety, one with a lanthanide label and the other with a dabcyl-
quencher molecule, provides an affordable approach when compared to 
double-labelled probes which are usually significantly more expensive than 
single-labelled oligonucleotides (Nurmi et al. 2001). Further, the design of the 
new probes is relatively simple since no complicated secondary structures are 
required for the functionality of the probes, such as for Molecular Beacons 
(Tyagi and Kramer 1996). The efficiency of the quenching of the signal by the 
quencher-oligonucleotide, in the approach where the label moiety and the 
quencher molecule are on opposite, complementary strands has already been 
demonstrated to be comparable to the characteristics of TaqMan probes and 
Molecular Beacons (Nurmi et al. 2002). The quenching efficiency was shown, 
also in this instance, to be quite high, with 97 % and 88 % of the signal 
quenched, when tested with the insulin-C-europium and insulin-T-terbium 












Figure 11. The hybridisation of the probes and the results of the insulin gene -2221 C/T and 
PVR-A/G assays. As shown in the upper part, depending on the sample genotype, in groups A 
and B only one of the probes produces a positive result indicating a homozygous sample, 
whereas in group C both probes are positive. If any of the samples failed to amplify, they 
would be shown in group D. In the lower part of the figure the insulin gene -2221 –results are 
marked with crosses and the PVR-results with open circles. The results showed the clear 
division of results into three distinct groups; A, B and C; based on their genotypes with no 
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The discrimination potential of short probes (Lipsky et al. 2001) was utilised 
by performing the hybridisation close to room temperature as opposed to the 
high temperatures used in TaqMan assays (Holland et al. 1991; Livak 1999). 
Even a G-T mismatch with minimal destabilising effect and cross-reactivity, 
that has been shown to complicate SNP typings (Ikuta et al. 1987; Luo et al. 
1996; Allawi and SantaLucia 1997; Bernard et al. 1998; Smit et al. 2001), 
could successfully be analysed in the insulin gene assay. 
 
An advantage in preventing the cross-reactivity is provided by the possibility 
of including both probes in the same reaction, enabled by the use of two 
lanthanide labels, europium and terbium, since only one probe can hybridise to 
one PCR product. Thus the probe with the completely complementary 
sequence has the advantage over the one with a single mismatch when 
competing for the same complementary strand (Livak 1999). 
 
 
5.2 HLA-DQB1 assay with LNA-spiked probes 
 
The second challenge was to apply the assay principle developed to a more 
complicated analyte, namely the HLA-DQB1 gene with its complex 
polymorphisms. The alleles are not defined by single SNPs, but rather a series 
of SNPs creating, in a sense, a haplotype that is called an allele. Although some 
alleles can be identified by probes covering a single SNP, or more typically 
two to three SNPs, there are alleles that can be distinguished only by a pattern 
produced by several probes covering multiple SNPs. 
 
Due to the complex nature of the DQB1-gene, the approach with competing 
probes for a single SNP could not be used. The probes used in the initial 
attempts to analyse the DQB1 alleles did not have any base analogs, but 
contained only DNA, similar to those used in the SNP assays (II, unpublished 
results). However, the signal-to-background ratios of these probes did not 
provide acceptable results, and thus those probes with only the quencher 
oligonucleotide to compete with the hybridisation to the PCR product did not 
provide a setting strict enough to attain adequate specificity.  
 
LNA additions were then made to the lanthanide-labelled probes to improve 
the functionality of the probes (II). LNAs are DNA analogs which have been 
shown to have strong affinity and high discriminatory power (Koshkin et al. 
1998; Braasch and Corey 2001; Petersen and Wengel 2003; Ugozzoli et al. 
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2004). The structure of the LNA is conformationally restricted with an extra 
methylene bridge in the ribose ring. This structure enables a very efficient 
binding to complementary nucleic acids (Latorra et al. 2003; Vester and 
Wengel 2004; Yang et al. 2007). LNAs have been used to improve the 
discriminatory power of different assays. For example, LNAs have been added 
to probes that fail to reliably differentiate genotypes, and also to primers to 
enhance their specificity and strength of binding to targets (Jacobsen et al. 
2002; Simeonov and Nikiforov 2002; Latorra et al. 2003; Letertre et al. 2003; 
Arjomand-Nahad et al. 2004; Kennedy et al. 2006). As shown by the 
comparisons of LNA-spiked probes with traditional only-DNA containing 
probes (II) this superior discrimination enabled a practical DQB1-assay set up. 
 
A set-up mimicking that of an existing DELFIA® HLA-DQB1-assay designed 
for the analysis of T1D risk alleles was first developed with six probes 
identifying the DQB1*02, *0301, *0302, *0602, *0603 and *0604 alleles (II, 
unpublished) (Figure 12). A control probe with a consensus sequence found in 
all DQB1 alleles was included to ensure the successful amplification of the 
samples. A corresponding chart for the additional probes, *0301/3, *04, *04/5, 
*0501 and *05/6, designed later for a more detailed typing of the DQB1 
alleles, is shown in Figure 13 (unpublished). The positive average signal-to-
background ratios for each probe were calculated from all samples positive for 
the typed allele. (For example, the *02 probe has an average signal-to-
background ratio of 3.09 for samples positive for *02 allele.) The signal-to-
background ratios for those alleles not recognised by the probe were calculated 
from all those samples which were positive for the allele in question, but not 
the allele the probe hybridises to. (For example, the *02 probe has an average 
signal-to-background ratio of 0.86 for those *0301 positive samples which are 
not positive for the *02 allele.) Average signal-to-background ratios of these 
probes ranged from 1.7 to 4.5 with positive samples and remained below 1.2 
for negative samples providing unambiguous typing results.  
 

















































Figure 12. The average signal-to-background ratios of the HLA-DQB1 probes used for typing 
of the alleles important for assessing the relative genetic risk for T1D. The probes used are 
marked on the right and the average signal-to-background ratios of samples containing a 
specified allele on the left. Alleles marked with *0502/3 denote both *0502 and *0503 alleles 
and were not differentiated by the assay. 
 
The bases in the probes substituted with LNA were chosen based on the 
differences in sequence between the allele or alleles recognised by the probe in 
question and all other possible sequences. LNA was usually added to the most 
critical bases differing between the targeted sequence and the majority of the 
other alleles, in order to provide the greatest possible difference between 
melting temperatures. However, too many LNA additions might have raised 
the melting temperature (Tm) of the probe too high, and destroyed the 
specificity achieved by the use of short probes. Therefore, the number of LNA-
bases per probe was limited to between two and five, depending on the probe 
sequence and its GC-content (II, unpublished results). 
 
















































Figure 13. The average signal-to-background ratios of the HLA-DQB1 probes used for more 
detailed typing of DQB1 alleles. The *0301/3-probe hybridises to both *0301- and *0303-
alleles; similarly the *04/5-probe recognises all *04- and *05-alleles and the *05/6-probe all 
*05- and *06-alleles. 
 
The results of an assay comprising all the possible probes available in the 
homogeneous assay format developed for the typing of HLA-DQB1 alleles are 
shown in Table 5. The signal-to-background ratios from each probe and the 
genotype of the sample that can be deduced from these results are shown. 
Some of the sample genotypes can not be resolved completely due to possible 
homozygosity that is not revealed by the assay (only one allele as a result). 
Furthermore, due to the multiple alleles recognised by some probes, other 
possible alleles that might be present, but remain concealed, are in parenthesis. 
For example a *0301(0303) result might be a *0301 homozygote or the 
genotype of the sample could be *0301/0303. Moreover, the *0602/3/4 result 
could consist of a sample with a combination of *0602, *0603 and *0604 
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Table 5. The results of a homogeneous assay for typing HLA-DQB1 alleles. The positive 
signal-to-background ratios are marked in bold. The resulting DQB1-genotype of the sample 
that can be deduced from the results is shown. For some of the samples a detailed genotype 
could not be identified and possible second alleles are set in parenthesis. The cut-off values set 
for each probe are also shown together with the average signal-to-background ratios for both 
positive and negative samples. (unpublished) 
 
allele 1 allele 2 *02 *0302 *0301 *0301/3 *04 *04/5 *05/6 *0501 *0602/3 *0603/4 control
*02 *0301 2,54 0,59 2,59 3,00 1,27 1,00 1,05 1,00 0,81 0,68 3,02
*0302 *0602 0,90 2,20 1,00 0,81 0,91 0,96 2,92 0,86 6,04 0,59 2,74
*0302 *0303 0,93 2,04 0,71 2,85 0,80 0,92 1,05 0,95 0,61 0,64 2,56
*0301 *0501 0,95 0,46 2,32 3,29 0,96 2,61 1,98 2,26 0,68 0,90 2,57
*04 *0602 0,92 0,45 1,07 0,72 2,25 2,65 3,82 1,13 6,38 0,65 3,08
*02 *0602 2,49 0,54 1,04 0,70 1,36 1,12 3,67 0,87 6,10 0,65 3,10
*04 *0602 1,06 0,53 1,12 0,74 2,30 2,65 3,65 1,04 6,39 0,77 3,02
*02 *0501 2,41 0,54 0,95 0,72 1,46 2,76 2,02 2,45 0,68 0,88 2,95
*04 *0501 0,98 0,48 0,93 0,69 2,58 3,08 2,02 2,75 0,82 0,93 2,66
*0302 0,94 3,68 0,71 1,03 1,11 1,15 1,03 0,96 0,64 0,71 2,85
*02 *0602 2,46 0,62 1,14 0,72 1,50 1,06 3,91 1,03 6,46 0,70 3,40
*0501 *0604 0,97 0,47 1,30 0,72 1,07 2,41 5,67 2,38 0,83 2,75 2,63
*0301 *0302 0,90 2,39 2,28 2,90 0,90 1,01 1,06 0,88 0,61 0,61 2,45
*02 *0501 2,38 0,53 0,91 0,70 1,28 2,35 2,01 2,47 0,62 0,96 2,78
*04 *0501 0,97 0,47 0,94 0,71 2,10 2,57 1,99 2,32 0,69 0,90 2,58
*0303 *05 0,89 0,47 0,76 3,09 1,06 2,40 2,05 0,86 0,63 0,86 2,58
*02 *05 2,37 0,51 0,80 0,76 1,18 2,38 1,35 1,02 0,60 0,78 2,55
*02 *0301 2,26 0,54 2,20 2,45 1,20 0,91 0,92 0,99 0,69 0,79 2,59
*0301 *04 0,88 0,45 2,54 3,10 2,31 2,64 0,94 1,07 0,59 0,68 2,40
*04 *0603 0,83 0,41 0,91 0,67 2,07 2,54 3,25 1,06 5,35 2,05 2,49
*02 *0301 2,27 0,54 2,41 2,81 1,24 0,97 0,93 0,88 0,70 0,62 2,51
*0301 *0603 0,87 0,45 2,38 2,87 1,04 1,06 3,65 1,00 5,92 2,35 2,67
*0301 (*0303) 0,96 0,51 2,96 3,75 0,90 0,82 1,15 0,98 0,61 0,68 2,54
*04 *0501 0,93 0,48 1,01 0,77 2,24 2,65 2,12 2,59 0,87 1,01 2,53
*0602/3/4 0,91 0,48 1,35 0,67 1,12 1,03 6,10 0,93 6,97 2,87 2,88
*0301 (*0303) 0,83 0,46 2,75 3,51 0,85 0,83 1,02 0,93 0,59 0,61 2,50
*0602 0,83 0,41 1,10 0,65 0,95 0,97 4,89 0,76 6,31 0,58 2,51
*0303 0,86 0,47 0,75 3,54 0,95 1,00 1,03 0,69 0,70 0,62 2,46
*0303 *05 0,89 0,44 0,70 2,84 0,99 2,35 2,06 0,83 0,59 0,87 2,30
*02 2,51 0,53 0,70 0,70 1,41 0,98 0,99 0,88 0,61 0,69 2,52
*02 *0603 2,16 0,49 0,98 0,65 1,22 0,97 3,18 0,86 5,73 2,12 2,88
*0602/3/4 0,88 0,44 1,15 0,63 1,08 1,08 5,42 1,26 5,43 2,21 2,70
*0301 *04 0,91 0,46 2,49 2,96 2,33 2,64 1,00 0,98 0,62 0,62 2,43
*0602/3/4 0,85 0,40 1,29 0,68 1,12 1,04 5,08 0,99 6,46 2,15 2,62
*02 *0301 2,43 0,57 2,61 3,12 1,31 1,16 1,01 1,00 0,78 0,70 2,64
*0301 (*0303) 0,83 0,43 2,20 3,56 0,83 0,89 1,09 0,83 0,57 0,56 2,15
*0301 *04 0,85 0,44 2,68 3,23 2,20 2,49 0,99 0,92 0,61 0,67 2,43
*02 *0301 2,34 0,55 2,53 2,97 1,20 0,85 0,96 0,90 0,66 0,66 2,49
*02 *04 2,23 0,49 0,66 0,65 2,10 2,38 0,96 0,96 0,57 0,62 2,47
*0302 *05 0,88 2,42 0,96 0,83 1,05 2,43 1,92 0,81 0,58 0,84 2,31
*02 *04 2,17 0,49 0,65 0,66 2,19 2,47 0,90 0,99 0,63 0,59 2,50
*0302 *04 0,79 2,37 0,70 0,93 2,03 2,39 0,87 0,68 0,55 0,60 2,34
*0302 *0603 0,81 2,69 1,04 0,81 1,00 0,90 3,76 0,98 5,53 2,38 2,63
*02 *05 2,23 0,49 0,68 0,68 1,37 2,47 1,78 1,01 0,71 0,90 2,35
*0302 *05 0,87 2,63 0,88 0,85 1,16 2,60 1,43 0,87 0,65 0,91 2,34
1,50 1,50 1,50 1,50 1,70 1,50 1,30 1,50 1,50 1,50 1,50
2,35 2,55 2,50 3,10 2,23 2,54 3,14 2,46 6,08 2,36 2,62
0,13 0,50 0,22 0,33 0,15 0,17 1,40 0,17 0,48 0,30 0,25
0,90 0,49 0,93 0,74 1,12 0,99 1,00 0,94 0,66 0,73
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The general levels of the signal-to-background ratios for positive samples are 
above 2.0 and the cut-off values were set for most probes at 1.50. The 
exceptions were the *04-probe, for which the cut-off was set at 1.70, and the 
*05/6-probe with a cut-off value of 1.30. The *05/6-probe seems to, on many 
occasions, generate lower signal-to-background ratios when an *05 allele is 
present, as is shown in Figure 13. Since the sequences of *05 and *06 alleles 
are identical at the probe binding site, the difference might be caused by the 
lower efficiency of amplification shown by the *05 alleles already in the 
DELFIA® based DQB1-assay (unpublished results). Further, the secondary 
structure of the PCR product at the probe binding site may cause the difference 
between the alleles, since the *05 alleles most likely have a stronger helix 
structure than the *06 alleles at the probe binding site (mfold web server, 
http://www.bioinfo.rpi.edu/applications/mfold, (Zuker 2003)) hindering the 
*05/6-probe from displacing the base pairing of the helix and binding to the 
PCR product. 
 
The cut-off value for the *04-probe was set at 1.70, slightly higher than for the 
majority of the probes, to ensure correct genotyping. The cross-reactivity 
shown by this probe seems to be greatest for those samples positive for the 
DQB1*02 allele. A possible explanation for this might be the presence of a G-
T-mismatch between the *04-probe and the PCR product of a DQB1*02 allele. 
This base pair in other non-*04 alleles is a G-C mismatch which is known to be 
more destabilizing than the G-T mismatch (Ikuta et al. 1987; Allawi and 
SantaLucia 1997). Since the *04/5-probe must also give a positive result for 
*04 positive samples, the information provided by this probe can be used to 
ascertain the *04 result. 
 
When the full DQB1 genotype of a sample has to be attained, it is valuable to 
be able to deduce whether a sample giving a positive result for only one allele 
is homozygous, or if there is a second allele not typed by the assay. This, 
however, is not possible with the assay developed, since it has been designed to 
be only qualitative. No unambiguous difference in the signal-to-background 
ratios has been observed between homozygous and heterozygous samples even 
when the differences in amplification efficiency have been taken into account. 
If the homoxygosity of a sample has to be confirmed, sequencing is required. 
 
Based on the application and allele information required, different 
combinations of the available probes can be chosen for an assay. For example, 
the typing of the genetic component for celiac disease would require the 
investigation of the DQB1*02 and *0302 alleles (Mäki et al. 2003; Reinton et 
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al. 2006; Ollikka et al. 2009), but does not benefit from the information 
provided by the other probes rendering them useless in this analysis. As 
demonstrated by the chosen approach for the primary screening step for the 
TEDDY study, the numbers of samples requiring further, more detailed 
genotyping can easily be reduced by the proper selection of the alleles typed. 
The most economical scheme can vary from the detection of only one or a few 
alleles in the primary step to the typing of as many alleles as possible at once, 
depending on the required genotype information.  
 
Due to several simultaneous screening programs requiring slightly different 
DQB1 information, the primary screening step has been further adjusted from 
the one published for the TEDDY screening strategy. The availability of the 
array of DQB1 probes, presented in Table 4, has enabled the number of probes 
utilised in the primary screening step to be increased. This allows the detection 
of the most important DQB1 alleles influencing disease risk assessment in the 
current screening programs. This approach has further diminished the necessity 
of secondary screening steps using DELFIA® technology than was used in the 
original TEDDY screening strategy (unpublished). 
 
The use of whole blood dried on sample collection paper as sample material 
was successfully adapted to the assay method. Since the direct use of paper 
discs in the reaction was not possible (unpublished), a simple method for 
liberating the DNA from the discs was developed that was also suited for large-
scale sample processing (II, III). The collection paper is a very convenient 
method for the handling and shipping of blood samples: only a small volume of 
blood is needed, the samples can be stored at room temperature, and possible 
spills of potentially biologically hazardous material are avoided. The minimal 
space these samples take up is also a very important aspect when large 
numbers of samples are to be shipped or stored. An added benefit of this 
sample pre-treatment method is the reduced consumption of the original 
sample material, an important fact when the sample is scarce and multiple 
genetic assays are to be performed from a single sample.  
 
 
5.3 HLA-B*27 screening with a dry reagent approach 
 
In the interest of simplifying the method developed even further, a dry 
chemistry application aimed at the screening of the HLA-B*27 allele was 
tested and compared to the DELFIA® method used in routine screening 
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(Välimaa et al. 1998). The principle of the probe chemistry remained the same, 
but the specificity of the B*27 assay relied heavily on allele specific primers in 
contrast to the SNP assays presented and the HLA-DQB1 screening where the 
probes are solely responsible for the genotyping. Further, a second pair of 
primers producing a second amplicon, namely a portion of the β-actin gene, 
was also required to control the success of amplification: the primers used to 
amplify the B*27 alleles did not amplify the other HLA-B alleles. Thus, any 
negative B*27 result required an assurance that it was a true negative result and 
was not due to failure in amplification. 
 
The dry reagents were shown to be stable at room temperature (Figure 14) at 
least up to eighteen weeks, and since no clear decline in the signals was shown 
during this period, it could be speculated that even longer storage would be 
possible. Storing the reagents at lower temperatures would most likely result in 
an even longer shelf-life (Glynou et al. 2007; Hagren et al. 2008). The reagents 
were successfully air-dried in sealed containers with desiccant without the use 
of any sophisticated instrumentation, a simple and inexpensive approach. The 
separation of the enzyme from the other reagents was shown to be necessary, 
and was accomplished by drying it into a separate well. If a method providing 
the separation of the enzyme from the other reagents within the reaction vessel 
was available, all the reagents could be placed directly into the PCR well, and 
the performance of the assay would consist only of the adding of the sample 
and optionally water. 
 
The performance time of the homogeneous assay was compared to a 
corresponding heterogeneous assay based on the DELFIA® technique. The 
homogeneous method, using dried reagents, required hours less hands-on time 
when compared to the DELFIA® assay and it could be performed within three 
to four hours depending on the speed of the thermal cycler. The DELFIA® 
assay, with its multiple steps, would require at least three hours longer. In 
addition, the savings achieved with the homogeneous approach in reagent and 
material costs due to the omitted, separate hybridisation step, were significant. 
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Figure 14. The stability of the dried reagents for the typing of HLA-B*27. The B*27 positive 
samples are marked with filled circles and the negative samples with open circles. The ratio of 
the terbium-labelled B*27-probe and the Eu-labelled control probe is shown on the y-axis and 
the time of storage on the x-axis. Four HLA-B*27 positive and three negative samples were 








In this study, the principle of a genotyping method based on competing 
hybridisation (Morrison et al. 1989; Li et al. 2002; Shengqi et al. 2002) was 
described and demonstrated to be applicable to both SNP assays as well as 
more complicated sequence analysis. LNA-base substitutions at critical bases 
in the oligonucletide probes were used to enhance the specificity of the probes 
in the assays aimed at HLA polymorphisms. The possibility of a dry reagent 
approach was explored with an assay developed for the detection of the HLA-
B*27 allele.  
 
The main conclusions based on the original publications are as follows: 
 
I The principle of the homogeneous assay based on asymmetric PCR and 
competitive hybridisation was shown to be applicable to three different SNP 
assays from three different genes investigated for possible associations to the 
susceptibility to type I diabetes. With the simple probe structure of a single 
label per oligonucleotide, the costs of the probes per assay are minimal. The 
expenses of the assay are mostly due to other reagents and consumables needed 
in the assay, all of which are commonly quite inexpensive and generally used, 
such as the DNA-polymerase, dNTPs and PCR plates and sealers. Combined 
with the use of only two instruments, a thermal cycler and a time-resolved 
fluorescence counter, this method is an easily adaptable and cost-effective 
approach to genotyping SNPs. 
 
II The assay principle developed was successfully applied to a more 
complicated analyte, the HLA-DQB1-gene, where due to the unique character 
of the DQB1-gene sequence, the competition between two probes aimed at a 
single SNP used in the three previous assays could not be exploited. Instead the 
required specificity of the probes had to be attained with the help of LNA-base 
substitutions at critical bases to the lanthanide-labelled probes. The 
functionality and specificity of the LNA-spiked probes were shown to be 
superior to their DNA-only counterparts. Further, the possibility of using whole 
blood dried on sample collection cards instead of extracted DNA was explored, 
and a method of liberating the DNA from the card into solution was developed 
and applied.  
 
III The HLA-DQB1-assay was further developed into a form that could be 
used as a primary screening step for a study comprising the genotyping of 
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thousands of samples for the estimation of genetic risk for type 1 diabetes. An 
efficient screening system enables the exclusion of ineligible individuals as 
early in the screening system as possible to avoid unnecessary costs by 
multiple screening rounds. The addition of a probe recognizing the DQB1*05 
and *06 alleles in the primary screening was proven to be an effective 
approach with only 16.5 % of the general population samples requiring further 
genotyping. With little hands-on time and with only 4 hours total time needed 
to perform the assay, the homogeneous assay format is a suitable and cost-
effective way of initiating the screening.  
 
IV A further simplification of the method was introduced to the assay for 
the presence of the HLA-B*27 allele as a dry-reagent concept, where all the 
reagents required to perform the assay, excluding the sample, are dried into the 
reaction vessel. When the actual assay is performed, only water and the sample 
need to be added to the vessels. The reagents were shown to be stable at room 
temperature for at least 18 weeks, enabling easy shipping and storage of 
reagents. In lower temperatures the reagents could, in all probability, be stored 
for even longer periods. The assay developed also compared favourably with 
the original DELFIA®-based assay when assay performance and costs were 
considered. 
 
The assay method developed has been shown be adaptable to both SNP 
analysis as well as more complicated sequence analysis, and it can be 
speculated that other types of polymorphisms, such as deletions and insertions, 
might also be possible targets for successful analysis. The main drawback of 
the assay is the current availability of only two labels, europium and terbium, 
which are suitable for this approach, and the limitations of multiplexing due to 
this fact. The use of prompt fluorophores in addition to the two time-resolved 
labels might offer an opportunity to increase the number of analytes detected 
from a single reaction. However, the unique characteristics of the lanthanide 
labels render them especially suitable for the analysis of crude sample material, 
such as whole blood dried on sample collection cards, as the impurities of this 
type of samples generate difficulties in the use of many other conventional 
fluorescent labels (Soini and Lövgren 1987; Iitiä et al. 1992; Nurmi et al. 
2000a; Nurmi et al. 2000b). If purified DNA is to be used as a sample or if a 
convenient method for extracting DNA from crude samples or purifying it to 
an acceptable degree were available, these labels could be combined for the 
simultaneous detection of several analytes (Nurmi et al. 2002). Another 
possibility enabling the use of whole blood dried on sample collection cards 
might be the use of several different assay chemistries based on the use of 
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time-resolved fluorometry and lanthanide labels allowing the detection of 
several analytes from a single well (Laitala et al. 2007; Ollikka et al. 2009). 
 
As our knowledge of the genetic components behind the development of T1D 
increases, a method for the typing of all these polymorphisms for the accurate 
estimation of the genetic risk becomes essential. However, as long as the other 
environmental factors remain elusive and a reliable prevention method or a 
cure is not available, the main use of these screening systems will be in studies 
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